Immunological risk factors for infection after immunosuppressive and biologic therapies

被引：1
|
作者：
Carbone, Javier [1 ]
del Pozo, Nadia [1 ]
Gallego, Antonio [1 ]
Sarmiento, Elizabeth [1 ]
机构：
[1] Univ Hosp Gregorio Maranon, Dept Clin Immunol, Transplant Immunol Grp, Madrid 28007, Spain
来源：
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2011年 / 9卷 / 04期
关键词：
biologic therapy; biomarkers; cellular immunity; humoral immunity; immune monitoring; immunosuppressive therapy; infection; risk factors; ORGAN TRANSPLANT RECIPIENTS; STEM-CELL TRANSPLANTATION; REMITTING MULTIPLE-SCLEROSIS; NON-HODGKIN-LYMPHOMA; RHEUMATOID-ARTHRITIS; T-CELLS; LIVER-TRANSPLANTATION; LUNG TRANSPLANTATION; RITUXIMAB TREATMENT; CYTOMEGALOVIRUS DISEASE;
D O I：
10.1586/ERI.10.178
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Immunosuppressive and biologic therapies are costly and can involve a considerable risk of infection. Noninvasive diagnostic tools for early prediction of infection before and after administration of these therapies are of major interest. Serial longitudinal immune monitoring would provide data on immunocompetence and complement clinical follow-up protocols. Biomarkers of immune response may be useful to identify patients at risk of developing infection and who could be candidates for immunosuppressant dose reduction. This article focuses on the potential use of biomarkers of immune response to predict development of infection after immunosuppressive and biologic therapies in selected settings of autoimmune disease (rituximab for treatment of rheumatoid arthritis) and solid organ transplantation.
引用
收藏
页码：405 / 413
页数：9
相关论文
共 50 条
  • [41] Risk of serious infection associated with biologic therapies in psoriasis: A prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
    Yiu, Z. Z.
    Smith, C. H.
    Ormerod, A.
    Ashcroft, D. M.
    Lunt, M.
    Walton, S.
    Murphy, R.
    Reynolds, N.
    Griffiths, C. E.
    Warren, R. B.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (10) : S193 - S193
  • [42] The Association between Psychosocial and Age-Related Factors with Adherence to Immunosuppressive Therapies after Renal Transplantation
    Zachcial, Justyna
    Uchmanowicz, Izabella
    Czapla, Michal
    Krajewska, Magdalena
    Banasik, Miroslaw
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [43] THE RISK FACTORS AND THE THERAPY FOR CHRONIC DIARRHEA RELATED TO IMMUNOSUPPRESSIVE AFTER RENAL TRANSPLANTATION
    Wen, Jiqiu
    Li, Leishi
    Chen, Jinsong
    Cheng, Dongrui
    Sun, Qiquan
    Ji, Shuming
    Liu, Zhihong
    [J]. TRANSPLANT INTERNATIONAL, 2009, 22 : 277 - 277
  • [44] Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors
    Schachtner, Thomas
    Stein, Maik
    Reinke, Petra
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2017, 19 (03)
  • [45] Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study
    Yamamoto, Takayuki
    Spinelli, Antonino
    Suzuki, Yasuo
    Saad-Hossne, Rogerio
    Teixeira, Fabio Vieira
    de Albuquerque, Idblan Carvalho
    da Silva, Rodolff Nunes
    de Barcelos, Ivan Folchini
    Takeuchi, Ken
    Yamada, Akihiro
    Shimoyama, Takahiro
    da Silva Kotze, Lorete Maria
    Sacchi, Matteo
    Danese, Silvio
    Kotze, Paulo Gustavo
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2016, 4 (06) : 784 - 793
  • [46] IMMUNOLOGICAL ASPECTS OF CANDIDA INFECTION COMPLICATING STEROID AND IMMUNOSUPPRESSIVE DRUG THERAPY
    FOLB, PI
    TROUNCE, JR
    [J]. LANCET, 1970, 2 (7683): : 1112 - &
  • [47] THE CURRENT USE OF IMMUNOSUPPRESSIVE THERAPY TO OVERCOME IMMUNOLOGICAL RISK-FACTORS ASSOCIATED WITH RENAL-ALLOGRAFT REJECTION
    SANFILIPPO, F
    [J]. TRANSPLANTATION AND CLINICAL IMMUNOLOGY, VOL XX: COMBINED IMMUNOSUPPRESSIVE THERAPY IN TRANSPLANTATION, 1989, 14 : 107 - 118
  • [48] Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
    Yiu, Zenas Z. N.
    Smith, Catherine H.
    Ashcroft, Darren M.
    Lunt, Mark
    Walton, Shernaz
    Murphy, Ruth
    Reynolds, Nick J.
    Ormerod, Anthony D.
    Griffiths, Christopher E. M.
    Warren, Richard B.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (03) : 534 - 541
  • [49] RETENTION OF BIOLOGIC AND IMMUNOLOGICAL ACTIVITY OF HGH AFTER REDUCTION AND ALKYLATION
    CONNORS, MH
    VINIK, A
    KAPLAN, SL
    GRUMBACH, MM
    [J]. PEDIATRIC RESEARCH, 1972, 6 (04) : 351 - &
  • [50] Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies
    Davis, Mitchell S.
    Spencer, Riley K.
    Johnson, Chandler E.
    Elhage, Kareem G.
    Jin, Joy Q.
    Hakimi, Marwa
    Bhutani, Tina
    Liao, Wilson
    [J]. DERMATOLOGY AND THERAPY, 2024, 14 (01) : 15 - 30
12345